Director at Outlook Therapeutics (NASDAQ: OTLK) buys 29,000 shares

Rhea-AI Filing Summary

Outlook Therapeutics director Yezan Munther Haddadin bought 29,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.8326 per share. Following this transaction, he directly holds a total of 66,167 Outlook Therapeutics shares.

Insider Trade Summary

Net Buyer: 29,000 shares ($24,145)

Net Buy 1 txn

Insider Haddadin Yezan Munther

Role null

Bought 29,000 shs ($24K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	29,000	$0.8326	$24K

Holdings After Transaction: Common Stock — 66,167 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 29,000 shares Purchase price: $0.8326 per share Shares owned after trade: 66,167 shares +1 more

4 metrics

Shares purchased 29,000 shares Open-market purchase of Common Stock

Purchase price $0.8326 per share Average price for the transaction

Shares owned after trade 66,167 shares Direct holdings following the purchase

Net buy shares 29,000 shares Net change in holdings from this Form 4

Key Terms

open-market purchase, Common Stock, Form 4, non-derivative

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for the Common Stock trade"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) describing the director’s transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"transaction_type: "non-derivative" indicating a direct stock trade"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haddadin Yezan Munther

(Last) (First) (Middle)

C/O OUTLOOK THERAPEUTICS, INC.

111 S. WOOD AVE, UNIT #100

(Street)

ISELIN NEW JERSEY 08830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		P		29,000	A	$0.8326	66,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Lawrence Kenyon, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Outlook Therapeutics (OTLK) report for Yezan Munther Haddadin?

Outlook Therapeutics reported that director Yezan Munther Haddadin executed an open-market purchase of 29,000 shares of Common Stock. The transaction reflects a direct addition to his personal holdings rather than an option exercise or non-market-related transfer.

At what price did the Outlook Therapeutics (OTLK) director buy shares?

The director purchased 29,000 Outlook Therapeutics shares at an average price of $0.8326 per share. This figure comes from the reported transaction price and represents the cost basis for this specific open-market acquisition on the reported date.

How many Outlook Therapeutics (OTLK) shares does Yezan Munther Haddadin own after this trade?

After the open-market purchase, Yezan Munther Haddadin directly owns 66,167 shares of Outlook Therapeutics Common Stock. This total includes the newly acquired 29,000 shares and is reported as his direct ownership position following the transaction.

Was the Outlook Therapeutics (OTLK) insider trade a buy or a sell?

The reported insider transaction was a buy. The Form 4 classifies it as an open-market purchase, with 29,000 shares of Common Stock acquired and no corresponding sales, resulting in a net increase in the director’s holdings.

Did the Outlook Therapeutics (OTLK) Form 4 involve derivative securities or options?

This Form 4 shows only a non-derivative transaction in Common Stock. The derivative section is empty, indicating no option exercises, warrants, or other derivative trades were reported in connection with this specific insider transaction.